查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1771691

美國胃癌診斷市場規模、佔有率、趨勢分析報告：按產品、疾病類型、最終用途、細分市場預測，2025-2033

U.S. Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric Lymphoma), By End-use (Diagnostic Laboratories), And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國胃癌診斷市場摘要

美國胃癌診斷市場規模預計在2024年達到4.8909億美元，預計到2033年將達到8.972億美元，2025年至2033年的複合年成長率為7.08%。由於診斷技術的進步、患者認知度和教育水平的提高以及新興市場醫療基礎設施的不斷完善，美國胃癌診斷市場正在不斷擴張。根據美國癌症協會 (ACS) 的數據，預計2024年美國新患者和死亡人數分別為26,890例和10,880例；2025年新患者和死亡人數分別為30,300例和10,780例。

液態切片、次世代定序(NGS) 和基於人工智慧的成像等技術創新正在推動市場成長。這些工具能夠實現更早的檢測、更精準的分期和更清晰的腫瘤生物學特性描述，從而製定更個人化和有效的治療方案。窄帶成像和共聚焦雷射內視鏡等先進的內視鏡技術提高了診斷準確性和患者預後。分子診斷的整合還能實現基於基因圖譜的標靶治療。技術進步正在推動市場需求，因為醫療保健提供者和研究人員正在尋求更精準、侵入性更小的治療方法，與傳統方法相比，能夠提供更快的結果、更高的靈敏度和更少的患者不適感。

由政府、非政府組織和醫療保健提供者主導的公眾意識提升宣傳活動和教育計劃正在提高人們對胃癌狀和風險因素的認知，進一步推動市場成長。例如，胃癌希望是一個全國性的非營利組織，它將在 2025 年 5 月的 ASCO 年會上發揮關鍵作用，該組織透過宣傳、教育、患者支持和國家立法夥伴關係來促進胃癌和胃食道癌的早期發現、治療和認知。這種認知的提高正在鼓勵人們更多地參與早期諮詢和篩檢計劃。此外，提高健康素養和獲取線上醫療資訊使患者能夠及時尋求診斷和適當的治療。隨著患者和看護者變得更加積極主動，對準確和可及的診斷服務的需求也日益增加。這種趨勢在新興國家很重要，這些國家的宣導活動正在縮小醫療保健利用的差距，刺激診斷技術市場的成長。

醫療基礎設施的不斷擴大是美國胃癌診斷市場發展的促進因素之一。美國對醫療基礎設施的持續投資，尤其是在醫療資源匱乏和農村地區，改善了人們獲得診斷服務的機會，包括內視鏡檢查和先進的胃癌影像技術。聯邦政府資助的計畫和不斷擴大的醫院網路旨在解決差異，使胃癌高危險群（如亞裔美國人和西班牙裔社區）能夠更早發現並取得更好的治療效果，因為這些人群的胃癌發病率相對較高。這些措施透過增加對診斷工具的需求來支持市場的成長。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國胃癌診斷市場變數、趨勢與範圍

  • 市場展望
    • 母市場展望
    • 相關/輔助市場展望。
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國胃癌診斷市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國胃癌診斷市場：產品評估與趨勢分析

  • 2024年及2033年的產品市場佔有率
  • 細分儀表板
  • 美國胃癌診斷市場：產品變化分析
  • 美國胃癌診斷市場規模及趨勢分析（依產品，2021-2033）
  • 2021-2033年美國胃癌診斷市場收益估計及預測
  • 試劑和耗材
  • 裝置

第5章美國胃癌診斷市場：依疾病類型估計與趨勢分析

  • 2024 年及 2033 年各疾病類型的市場佔有率
  • 細分儀表板
  • 美國胃癌診斷市場：疾病類型展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 腺癌
  • 胃淋巴瘤
  • 其他

第6章美國胃癌診斷市場：最終用途估計與趨勢分析

  • 2024年及2033年最終用途市場佔有率
  • 細分儀表板
  • 美國胃癌診斷市場：按最終用途分類的展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 醫院
  • 診斷實驗室
  • 診斷影像

第7章美國胃癌診斷市場：各國估計與趨勢分析

  • 2024 年及 2033 年各國市場
  • 各國市場儀表板
  • 美國市場概述
  • 市場規模、預測趨勢分析，2021-2033年：
  • 美國
    • 主要國家趨勢
    • 法規結構/報銷
    • 競爭場景

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • Key company market share analysis, 2024
    • Illumina, Inc.
    • Guardant Health
    • Natera, Inc
    • GE Healthcare.
    • Thermo Fisher Scientific Inc.
    • QIAGEN
    • Freenome Holdings Inc
    • Exact Sciences Corporation
    • PathAI
Product Code: GVR-4-68040-632-5

U.S. Gastric Cancer Diagnostics Market Summary

The U.S. gastric cancer diagnostics market size was estimated at USD 489.09 million in 2024 and is projected to reach 897.20 million by 2033, and growing at a CAGR of 7.08% from 2025 to 2033. The U.S. gastric cancer diagnostics market is expanding due to advancements in diagnostic technologies, increasing awareness and patient education, and the expansion of healthcare infrastructure in emerging markets. According to the American Cancer Society (ACS) in 2024, gastric cancer accounted for 26,890 new cases and 10,880 deaths in the U.S. In addition, 30,300 new cases and 10,780 deaths are estimated in the U.S. for the year 2025.

Technological innovations such as liquid biopsies, next-generation sequencing (NGS), and AI-based imaging are propelling the market growth. These tools enable early detection, improved staging, and better characterization of tumor biology, leading to more personalized and effective treatment plans. Advanced endoscopy techniques, like narrow-band imaging and confocal laser endomicroscopy, enhance diagnostic accuracy and patient outcomes. Integration of molecular diagnostics also allows for targeted therapies based on genetic profiles. As healthcare providers and researchers push for more precise, less invasive methods, technological progress boosts market demand, offering faster results, better sensitivity, and reduced patient discomfort compared to traditional methods.

Public awareness campaigns and educational initiatives led by governments, NGOs, and healthcare providers are further fueling market growth by improving recognition of gastric cancer symptoms and risk factors. One such example is Hope for Stomach Cancer, a national nonprofit organization that will play a key role at the May 2025 ASCO Annual Meeting, advancing early detection, treatment, and awareness of stomach and gastroesophageal cancers through advocacy, education, patient support, and national legislative partnerships. This increased awareness is prompting earlier medical consultations and higher participation in screening programs. Moreover, the rise in health literacy and access to online medical information empowers patients to seek timely diagnosis and appropriate care. As patients and caregivers become more proactive, the demand for accurate and accessible diagnostic services grows. This trend is vital in emerging economies, where awareness efforts are narrowing the gap in healthcare utilization and fueling market growth for diagnostic technologies.

The expansion of healthcare infrastructure associated with developing nations is one of the drivers in the U.S. gastric cancer diagnostics market through a different lens, namely, health equity and outreach. In the U.S., ongoing investments in healthcare infrastructure, especially in underserved and rural areas, are improving access to diagnostic services, including endoscopy and advanced imaging for gastric cancer. Federally funded programs and hospital network expansions aim to bridge disparities, enabling earlier detection and better outcomes in high-risk populations such as Asian American and Hispanic communities, where gastric cancer prevalence is comparatively higher. These efforts support market growth by increasing demand for diagnostic tools.

U.S. Gastric Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. gastric cancer diagnostics market report based on product, disease type, end use:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Reagents & Consumables
  • Instruments
  • Disease Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Adenocarcinoma
  • Gastric lymphoma
  • Others
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic Laboratories
  • Diagnostic imaging

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease Type
    • 1.2.3. End use
    • 1.2.4. Country scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Disease type outlook
    • 2.2.3. End use outlook
    • 2.2.4. Country outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Gastric Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Gastric Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Gastric Cancer Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. U.S. Gastric Cancer Diagnostics Market: Product Movement Analysis
  • 4.4. U.S. Gastric Cancer Diagnostics Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
  • 4.5. U.S. Gastric Cancer Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Reagents & consumables
    • 4.6.1. Reagents & consumables Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Instruments
    • 4.7.1. Instruments Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Gastric Cancer Diagnostics Market: Disease Type Estimates & Trend Analysis

  • 5.1. Disease Type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. U.S. Gastric Cancer Diagnostics Market by Disease Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Adenocarcinoma
    • 5.5.1. Adenocarcinoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.6. Gastric lymphoma
    • 5.6.1. Gastric lymphoma Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. U.S. Gastric Cancer Diagnostics Market: End use Estimates & Trend Analysis

  • 6.1. End use Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. U.S. Gastric Cancer Diagnostics Market by End use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Diagnostic imaging
    • 6.7.1. Diagnostic imaging Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. U.S. Gastric Cancer Diagnostics Market: Country Estimates & Trend Analysis

  • 7.1. Country Market Share Analysis, 2024 & 2033
  • 7.2. Country Market Dashboard
  • 7.3. U.S. Country Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.5. U.S.
    • 7.5.1. Key country dynamics
    • 7.5.2. Regulatory framework/Reimbursement
    • 7.5.3. Competitive scenario
    • 7.5.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Illumina, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Guardant Health
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Natera, Inc
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. GE Healthcare.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Thermo Fisher Scientific Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. QIAGEN
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Freenome Holdings Inc
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Exact Sciences Corporation
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. PathAI
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
  • Table 3 U.S Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
  • Table 4 U.S Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in U.S.
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Gastric Cancer Diagnostics market: market outlook
  • Fig. 10 U.S. Gastric Cancer Diagnostics competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Gastric Cancer Diagnostics market driver impact
  • Fig. 16 U.S. Gastric Cancer Diagnostics market restraint impact
  • Fig. 17 U.S. Gastric Cancer Diagnostics market strategic initiatives analysis
  • Fig. 18 U.S. Gastric Cancer Diagnostics market: Product movement analysis
  • Fig. 19 U.S. Gastric Cancer Diagnostics market: Product outlook and key takeaways
  • Fig. 20 Reagents & consumables market estimates and forecasts, 2021 - 2033
  • Fig. 21 Instruments market estimates and forecasts,2021 - 2033
  • Fig. 22 U.S. Gastric Cancer Diagnostics Market: Disease type movement analysis
  • Fig. 23 U.S. Gastric Cancer Diagnostics market: Disease type outlook and key takeaways
  • Fig. 24 Adenocarcinoma market estimates and forecasts, 2021 - 2033
  • Fig. 25 Gastric lymphoma market estimates and forecasts, 2021 - 2033
  • Fig. 26 Others market estimates and forecasts, 2021 - 2033
  • Fig. 27 U.S. Gastric Cancer Diagnostics Market: End use movement analysis
  • Fig. 28 U.S. Gastric Cancer Diagnostics market: End use outlook and key takeaways
  • Fig. 29 Hospitals market estimates and forecasts, 2021 - 2033
  • Fig. 30 Diagnostic Laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 31 Diagnostic imaging market estimates and forecasts, 2021 - 2033
  • Fig. 32 U.S. Gastric Cancer Diagnostics market: Country movement analysis
  • Fig. 33 U.S. Gastric Cancer Diagnostics market: Country outlook and key takeaways
  • Fig. 34 U.S. Gastric Cancer Diagnostics market share and leading players
  • Fig. 35 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 36 Market share of key market players- U.S. Gastric Cancer Diagnostics market